Logo

Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma

Share this

Alcon Announces Global Removal of CyPass Micro-Stent for Surgical Glaucoma

Shots:

  •  Alcon is removing CyPass globally revealing its unmet needs with safety of patients with the guidance for surgeons to stop its further use and return the fresh devices
  •  The above decision is on the basis of five-year data from COMPASS-XT long-term safety study
  • The study showed reduction in intraocular pressure at two yrs- resulting a little difference in endothelial cell loss and at five yrs experienced reduction in endothelial cell loss vs cataract surgery alone
  • Sukamenak

Ref: Novartis | Image:  Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions